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63 Resveratrol improves chloride secretion in cystic ﬁbrosis mice
homozygous for the F508del mutation
A. Palem1, C. Bouckaert1, B. Dhooghe1, A. Leonard2, B. Lubamba1,
P. Wallemacq1, P. Lebecque2, T. Leal1. 1Universite Catholique de Louvain,
Centre for Toxicology and Applied Pharmacology, Brussels, Belgium; 2Universite
Catholique de Louvain, Pediatric Pulmonology & Cystic Fibrosis Unit, Cliniques
Saint Luc, Brussels, Belgium
Introduction: Resveratrol is a polyphenol found in red wine that possesses a wide
range of biological effects and has anti-oxidant properties. All these biological
effects are related to NF-úB pathway which it is thought to be dysregulated in CF
patients secondary to CFTR dysfunction.
Aim: To investigate the potential impact of resveratrol on CFTR function in CF
mice.
Methods: Three weeks apart, nasal potential difference measurements (NPD) were
performed in 5 CF mice homozygous for the F508del-CFTR mutation in the
129/FVB outbred background (a) without treatment (baseline) and (b) after intra-
peritoneal injection of resveratrol (20mg/kg) diluted in physiological serum. Normal
distribution of NPD measurements was conﬁrmed by Shapiro test. Between-groups
comparisons were evaluated using paired ANOVA coupled to t Test.
Results: Total chloride secretion improved from 4.8±3.5mV (baseline) to
11.7±3.4mV (Resveratrol) (P = 0.015). Baseline PD and response to amiloride were
not modiﬁed.
Conclusion: Total chloride secretion improved with resveratrol. These preliminary
data prompt us to further study the potential effect of resveratrol in cystic ﬁbrosis.
64* Correction of DF508-CFTR in human airway epithelia and ex vivo
rectal biopsies by s-cis-locked bithiazole corrector-29
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D.W. Nielson2, A.S. Verkman1. 1University of California, Departments of
Medicine & Physiology, San Francisco, United States; 2University of California,
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Defective CFTR chloride transport is a prominent feature in cystic ﬁbrosis (CF). The
s-cis-locked cycloheptathiazolothiazole 29 (corrector-29) was previously designed
and identiﬁed as the most potent bithiazole corrector of defective DF508-CFTR
with EC50 in vitro ~450 nM (Yu et al., J. Med. Chem. 51: 6044–6054, 2008).
However, its efﬁcacy in human tissues has not been reported.
The purpose of this translational study was to evaluate the efﬁcacy of corrector-29
on DF508-CFTR in human CF epithelia. We performed transepithelial short-circuit
current (Isc) measurements in primary cultures of human bronchial epithelial (HBE)
cells and ex vivo native rectal biopsies from DF508-CF and non-CF subjects. CFTR
immunoblot analysis was done on the same rectal biopsies.
After 24 h incubation at 37ºC with 10mM corrector-29, there was a vehicle-
independent, forskolin-stimulated increase in DF508-CFTR-mediated chloride se-
cretion of 5.4±0.3mA/cm2 (S.E.) in HBE cells (n = 8) and of 4.5±0.5mA/cm2
in rectal biopsies (n = 16), indicating ~25% of normal CFTR function in non-
CF controls. CFTR immunoblot analysis showed an increase in mature CFTR
protein (band C) in DF508-CF rectal biopsies incubated with corrector-29 but not
in untreated biopsies.
These data provide evidence for substantial DF508-CFTR correction by corrector-29
in disease-relevant human CF epithelia and support the utility of ex vivo assays
in native rectal tissue for CF drug development. Preclinical testing of candidate
CF drugs can help to prioritize and optimize compounds for translation into
clinical trials. This work was supported by CFF, CFRI and the Christiane Herzog
Foundation.
65 Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic
ﬁbrosis (nmCF): baseline data
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Background: Ataluren is an investigational drug that induces readthrough of
nonsense mutations to produce full-length, functional CFTR in patients with nmCF.
Methods: This Phase 3, randomized, double-blind, placebo-controlled study en-
rolled 238 patients 6 years of age with nmCF at >40 sites internationally
to receive ataluren 10 (morning), 10 (midday), 20 (evening) mg/kg or placebo
daily for 48 weeks. Standard outcome measures include spirometry, health-related
quality of life as assessed by the Cystic Fibrosis Questionnaire-Revised, and sweat
chloride. Novel outcome measures include assessment of pulmonary symptoms
and exacerbations using the Exacerbation of Chronic Pulmonary Disease Tool
with patient-reported data collected daily by mobile phone, objective cough rate
in the community setting as measured by an ambulatory recorder, nasal potential
difference using standardized equipment and procedures, and high-resolution chest
computed tomography.
Results: 238 patients (M/F = 121/117) were enrolled. Baseline characteristics
include median [range] age = 22[6−53] yrs and %-predicted FEV1 = 61[40−90].
Available baseline data relating to the use of the novel outcome measures will be
presented.
Conclusion: Ataluren therapy couples a patient’s genetic diagnosis with a mutation-
speciﬁc therapeutic approach designed to address the underlying genetic defect.
Pretreatment data from this study will augment understanding of disease severity in
the nmCF subpopulation and the feasibility of several innovative outcome measures.
Funded by PTC Therapeutics; Genzyme; and Cystic Fibrosis Foundation Therapeu-
tics, Inc
66 Synthesis of survival evidence in a model of cystic ﬁbrosis
disease progression
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Improved knowledge of CFTR protein defects has raised the possibility of treating
the cause of CF, which may improve survival. However, survival is an impractical
endpoint for CF trials. Intermediate outcomes that predict long-term survival may
provide tools for assessing the impact of novel CFTR therapy. We synthesized
published evidence to create such a tool and developed a model of mortality in CF
as a function of age and prognostic factors.
A systematic literature review of CF disease progression was performed in Medline
and Embase. Prospective or retrospective cohort and case-control studies that re-
ported mortality jointly with prognostic factors were accepted. Covariates of interest
included gender, lung function, weight-for-age, pancreatic sufﬁciency, diabetes, lung
microﬂora and number of acute exacerbations. Results were synthesized by Bayesian
meta-analysis techniques.
Seven studies, together including >20,000 patients, provided sufﬁcient published
data for the model. Survival over time was described with a Gompertz model
with its scale parameter affected by birth cohort, gender, lung function, respiratory
infection with Burkholderia cepacia and Staphylococcus aureus, diabetes, number
of exacerbations, and pancreatic sufﬁciency. The shape parameter was assumed to
be only affected by birth cohort.
According to our model, lung function is the main determinant of life expectancy
but other important factors include acute exacerbations, infections, diabetes and
pancreatic insufﬁciency. Patient characteristics and clinical endpoints from treatment
arms can be entered into the model to help predict and compare long-term outcomes.
